Efficacy and safety of unilateral biportal endoscopy vs. percutaneous endoscopic interlaminar approach in lumbar disc herniation: A meta-analysis​

单侧双通道内镜与经皮内镜椎板间入路治疗腰椎间盘突出症的疗效和安全性:一项荟萃分析

阅读:3

Abstract

Lumbar disc herniation (LDH) is a common cause of lower back and radicular pain. Unilateral biportal endoscopic discectomy (UBE) and percutaneous endoscopic interlaminar discectomy (PEID) are two prevalent minimally invasive techniques, yet their comparative efficacy and safety remain debated. Within the present meta-analysis, the aim was to compare the efficacy and safety of UBE and PEID in treating LDH. A systematic literature search was conducted using Web of Science, PubMed, Embase and the Cochrane Library up to June 10, 2025, to identify comparative studies evaluating UBE and PEID for single-level LDH. Extracted data included operative time, blood loss, fluoroscopy frequency, hospital stay, visual analog scale (VAS) score for back and leg pain, Oswestry Disability Index (ODI), MacNab excellent/good rate and complication rate. Study quality was assessed using the Newcastle-Ottawa Scale. A total of ten studies involving 1,003 patients was included. PEID demonstrated advantages in operative time [mean difference (MD)=7.82 min; P=0.004], blood loss (MD=25.5 ml; P=0.01) and hospital stay (MD=0.56 days; P=0.007). UBE demonstrated ODI improvement at 1 (MD=-0.93; P=0.01) and 6 months (MD=-0.85; P=0.01). No significant differences were observed in VAS scores for back and leg pain, MacNab excellent/good rate, fluoroscopy frequency or complication rates. UBE demonstrated improved postoperative functional recovery, instrument maneuverability and visualization, whereas PEID offered shorter operative time, reduced blood loss and shorter hospital stays. The choice of surgical approach should consider these outcome trade-offs along with patient characteristics and surgeon expertise.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。